Common Bacterial Strains Resistant to Tigecycline
Tigecycline, a glycylcycline antibiotic, shows reduced susceptibility or high resistance (MIC ≥8 mg/L) in certain Gram-negative bacteria, particularly those producing carbapenemases or efflux pumps that expel the drug. Key resistant strains include:
- Pseudomonas aeruginosa: Inherently resistant due to low outer membrane permeability and multiple efflux pumps like MexXY-OprM. Over 90% of isolates are resistant in surveillance data.[1]
- Proteus spp. (e.g., Proteus mirabilis, Proteus vulgaris): Naturally resistant from chromosomal AmpC beta-lactamases and efflux; MIC90 often >16 mg/L.[1][2]
- Providencia spp. (e.g., Providencia stuartii, Providencia rettgeri): High resistance rates (>80%) linked to intrinsic mechanisms and plasmid-mediated efflux.[1]
- Acinetobacter baumannii (some multidrug-resistant strains): Resistance emerges via AdeABC efflux overexpression or mutations; rates up to 30-50% in ICU settings.[2][3]
Gram-positive bacteria like Staphylococcus aureus and enterococci remain mostly susceptible, with resistance rare (<5%).[1]
Why These Strains Resist Tigecycline
Resistance stems from:
- Efflux pumps (e.g., Tet(A) in Enterobacterales, Mex in Pseudomonas).
- Enzymatic inactivation (rare, but ribosomal protection proteins like Tet(X) in emerging E. coli).
- Reduced uptake in non-fermenters like P. aeruginosa and Acinetobacter.[2]
No tigecycline-specific patents directly address resistance (DrugPatentWatch.com lists formulation patents expiring 2028-2032, but MIC data unchanged).[4]
Clinical Impact and Testing
In hospitals, resistance complicates treatment of ventilator-associated pneumonia or intra-abdominal infections. Labs use EUCAST breakpoints: resistant if MIC >2 mg/L for Enterobacterales, >1 mg/L for Acinetobacter.[3] Surveillance like SENTRY shows rising A. baumannii resistance in Asia-Pacific (40%).[1]
Alternatives for Resistant Infections
| Strain | Tigecycline Susceptibility | Preferred Alternatives |
|--------|-----------------------------|------------------------|
| P. aeruginosa | Low (95% resistant) | Colistin, ceftolozane-tazobactam |
| A. baumannii | Variable (50% resistant) | Sulbactam, eravacycline |
| Proteus/Providencia | Very low (<10% susceptible) | Fosfomycin, aminoglycosides[2] |
Monitor local antibiograms; combination therapy often needed.
Sources
[1] SENTRY Antimicrobial Surveillance (2010-2016)
[2] Tigecycline Resistance Mechanisms Review (Clin Infect Dis, 2018)
[3] EUCAST Breakpoints v12.0 (2022)
[4] DrugPatentWatch.com - Tigecycline Patents